P194 Once-Daily QVA149 Provides Superior Bronchodilation and Improves Lung Function Versus Twice-Daily Fluticasone/Salmeterol in COPD Patients: The ILLUMINATE Study

C Vogelmeier,P D’Andrea,V Alagappan,D Banerji,J Pallante,E He,H Bryant,E Bateman

doi:10.1136/thoraxjnl-2012-202678.255

P194 Once-Daily QVA149 Provides Superior Bronchodilation and Improves Lung Function Versus Twice-Daily Fluticasone/Salmeterol in COPD Patients: The ILLUMINATE Study

C Vogelmeier, P D’Andrea + Show 6 more

Open Access

https://doi.org/10.1136/thoraxjnl-2012-202678.255

Copy DOI

Journal: Thorax

Publication Date: Nov 19, 2012

Affiliation: Philipps University of Marburg, Tris Pharma (United States), Novartis (United States), Novartis (United Kingdom), University of Cape Town

#FEV1 AUC0 12h #Pre-dose Trough FEV1 + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

IntroductionQVA149 is a novel inhaled once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol and the long-acting muscarinic antagonist (LAMA) glycopyrronium, in development for the maintenance...

Full Text